Proven concept for sustained glucose elevation novel option for preventive treatment of CHI
Efpegerglucagon is a long-acting glucagon analog chemically conjugated with constant region of human immunoglobulin via non-peptidyl flexible linker.
The main physiological effects of glucagon receptor agonism (increasing glycogenolysis and gluconeogenesis) and favorable physicochemical and PK properties suggest therapeutic potential of Efpegerglucagon in subjects with chronic hypoglycemic diseases such as congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBH). Efpegerglucagon received orphan drug designation from the FDA, EMA, and MFDS for the treatment of CHI, and received rare pediatric disease designation from in the U.S FDA. Efpegerglucagon has also been designated as an orphan drug by the EMA for the treatment of insulin autoimmune syndrome.
Additionally, glucagon receptor agonism is also associated with increased energy expenditure and improvement of various cardiometabolic risk factors. In nonclinical studies, improved lipid profile, kidney function, and blood pressure were observed along with a remarkable weight loss effect.
A double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting
Potential Effect of a Novel Combination of GLP-1RA (efpeglenatide) and Long-Acting Glucagon Analog (HM15136) in Animal Models of Metabolic Disorders (657-P)
American diabetes association (ADA) 81st Scientific sessions, 2021
Sustained Glucagon Effect on Cardiovascular Renal and Metabolic Disorders Mediated by a Long-Acting Glucagon Analog, HM15136, in Animal Disease Models (658-P)
American diabetes association (ADA) 81st Scientific sessions, 2021
A double-blind, placebo-controlled single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting glucagon analogue, in healthy subjects
American diabetes association (ADA) 80th Scientific sessions, 2020
Sustained Glucagon effect on blood glucose and improvements of insulin resistance mediated by a novel long-acting Glucagon analogue, HM15136, in animal models
European association for the study of diabetes (EASD) 55th Annual meeting, 2019
Sustained Glucagon effect on blood glucose and improvements of insulin resistance mediated by a novel long-acting Glucagon analog, HM15136, in animal models
American diabetes association (ADA) 79th Scientific sessions, 2019
A novel long-acting Glucagon analog (HM15136) offers favorable stability, PK/PD, and therapeutic potentials in CHI (congenital hyperinsulinism) animal model
European association for the study of diabetes (EASD) 53rd Annual meeting, 2017